Search Results
Your search for ,twO matches 12066 pages
Showing 1101 - 1150Are Cannabinoids Safe and Effective for Reducing Symptoms in Pediatric Patients With Cancer?
Investigators have revealed that there may be a lack of evidence to inform the dosing, safety, and efficacy of cannabinoids for managing symptoms in pediatric patients with cancer, according to a recent systematic review and meta-analysis published by Chhabra et al in Cancer. Background Although...
Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
This is Part 1 of Novel Therapies for Advanced Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable. In this video, Drs. Aditya Bardia, Sara Tolaney, and Antonio C. Wolff discuss the treatment of hormone receptor–positive, HER2-negative...
CLL/SLL: Efficacy of CD19-Directed CAR T-Cell Therapy in Relapsed or Refractory Disease
In a phase I/II study (TRANSCEND CLL 004) reported in The Lancet, Tanya Siddiqi, MD, and colleagues found evidence of activity with the CD19-directed chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel in patients with relapsed or refractory chronic lymphocytic leukemia...
The Future Priorities of the National Cancer Institute
Fifty-two years ago, President Richard Nixon signed the National Cancer Act of 1971 into law, which established the National Cancer Institute (NCI) in its current form. At the time, the budget was $1.6 billion. Today, it is $7.8 billion, $4.5 billion less than the amount needed to keep up with...
Novel Targeted Therapy Combination May Be an Effective First-Line Option for Gastric or Gastroesophageal Junction Adenocarcinoma
Researchers have found that the novel targeted therapy zolbetuximab in combination with a standard chemotherapy may extend survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and overexpression of the claudin-18 isoform 2 protein (CLDN18.2), according to a novel...
Sacituzumab Govitecan-hziy Continues to Show Benefit in Patients With Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer
The antibody-drug conjugate sacituzumab govitecan-hziy continued to demonstrate superior benefit for patients with hormone receptor–positive, HER2-negative metastatic breast cancer when compared with standard chemotherapy, according to the final analysis of the phase III TROPiCS-02 study published...
Alcohol Consumption Behaviors Among Patients Diagnosed With Cancer
In a study from the National Institutes of Health All of Us Research Program reported in JAMA Network Open, Shi et al found that alcohol consumption and risky drinking behaviors were common among patients with a cancer diagnosis, including patients currently receiving treatment for their cancer....
Addition of Neoadjuvant Monoclonal Antibody to Platinum-Based Chemotherapy in Resectable NSCLC
In a Chinese phase II trial (TD-FOREKNOW) reported in JAMA Oncology, Lei et al found that the addition of neoadjuvant camrelizumab to platinum-based chemotherapy resulted in a higher pathologic complete response rate among patients with resectable stage IIIA or IIIB (T3N2) non–small cell lung...
Targeted Axillary Dissection After Neoadjuvant Therapy in Node-Positive Breast Cancer
In a German prospective registry study (SenTa) reported in JAMA Surgery, Kuemmel et al found that targeted axillary dissection alone after neoadjuvant systemic therapy was associated with outcomes similar to those obtained with targeted axillary dissection plus axillary lymph node dissection in...
Follicular Lymphoma: Novel Drug Combination Shows Benefit
In a phase II trial (ROSEWOOD) reported in the Journal of Clinical Oncology, Zinzani et al found that the addition of zanubrutinib to obinutuzumab significantly improved objective response rate among patients with relapsed or refractory follicular lymphoma. Study Details In the open-label trial,...
More on the Complexity of Prior Authorization
We read with interest the recent commentary by S. Monica Soni, MD, and Andrew A. Hertler, MD, FACP, on prior authorization (June 10, 2023, issue of The ASCO Post). The nuances of prior authorization in our health-care landscape are both complex and consequential. Conceived as a safeguard against...
How the Cancer Moonshot Aims to Improve the Quality of Life for Adolescent and Young Adult Cancer Survivors
Several recent studies have shown an increasingly disturbing trend: the incidence of early-onset cancers—those diagnosed in individuals younger than age 50—is on the rise, and not just in the United States but globally as well. Worldwide, in 2019, there were a reported 1.19 million new cases of...
Rapid Guideline Update Offers Key Evidence-Based Recommendations for Stage III NSCLC Management
A new ASCO guideline rapid update provides updated recommendations for the management of stage III non–small cell lung cancer (NSCLC). These updated recommendations made by the ASCO expert panel cover treatment options for patients with resected disease and specific genetic mutations as well as...
Unraveling the Mechanisms Behind the Antichemotherapy Effects of ABCG2 Proteins
Researchers may have discovered how to prevent the cellular-cleaning protein ABCG2 from removing chemotherapeutics from tumor cells, according to a recent study published by Gose et al in Nature Communications. These research findings may improve future cancer therapeutics. Background Most new...
Breast Cancer Screening and 10-Year Net Survival in Canadian Women Aged 40 to 49
In a Canadian study reported in the Journal of Clinical Oncology, Wilkinson et al found that breast cancer screening was associated with greater 10-year breast cancer net survival among women aged 40 to 49 living in jurisdictions including mammography screening programs for this age group, compared ...
Are All Benzodiazepines Created Equal in Terms of Survival in Patients With Pancreatic Cancer?
Patients with pancreatic cancer who were treated with the benzodiazepine lorazepam had shorter progression-free survival periods than patients who were not, according to study results published by Cornwell et al in Clinical Cancer Research. In contrast, patients who were treated with the...
ARTISTRY-7 and ROSELLA: Phase III Trials to Evaluate Novel Agents in Platinum-Resistant Ovarian Cancer
Platinum resistance occurs in almost all patients whose ovarian cancer recurs. Single-agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for effective treatment. At the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on...
New Challenge in Triple-Negative Breast Cancer: Optimizing the Sequencing of Treatments
New approaches are offering hope for better outcomes in metastatic triple-negative breast cancer, according to Suchita Pakkala, MD, of Emory University’s Winship Cancer Institute, Atlanta. She shared her thoughts on using PARP inhibitors and antibody-drug conjugates at the 2023 Debates and...
Ipilimumab Plus Nivolumab May Improve Outcomes in Patients With Refractory Metastatic Melanoma, Study Suggests
Researchers have discovered that ipilimumab in combination with nivolumab may be an effective second-line therapy in patients with PD-1 blockade–refractory metastatic melanoma, according to a recent study published by VanderWalde et al in Nature Medicine. These findings demonstrated the combination ...
Therapeutic Implications of DNA Repair Discoveries in Patients With Homologous Recombination Deficiencies
Long-molecule scars may help identify patients with BRCA1- and BRCA2-deficient cancer types, according to a recent study published by Setton et al in Nature. Background Once DNA is damaged by toxins, radiation, or normal cell division, human cells must continually fix DNA breaks to survive. When...
Does Benzo Type Impact Pancreatic Cancer Outcomes?
Pancreatic cancer has the poorest 5-year survival rate (12.5%) relative to all other cancers. In 2023, about 64,050 people will be diagnosed with pancreatic cancer, and approximately 50,550 will die of the disease. A retrospective study investigating the impact of palliative care medicine on the...
Four Novel Biomarkers May Help Detect Black Patients at Risk of Advanced Prostate Cancer
Researchers have identified a cell metabolism process found in male patients with West African ancestry who have diabetes and metastatic prostate cancer that could potentially lead to improved testing and treatments for Black patients with both diseases. The findings by Shuck et al were presented...
Effect of Atorvastatin on Cardiac Dysfunction in Patients Receiving Anthracyclines for Lymphoma
In a study (STOP-CA) reported in JAMA, Neilan et al found that atorvastatin reduced the risk of decreased left ventricular ejection fraction (LVEF) in patients receiving anthracycline-based chemotherapy for the treatment of lymphoma. Study Details In the U.S.-Canadian double-blind trial, 300...
Sacituzumab Govitecan-hziy Achieves Response After Disease Progression on Immune Checkpoint Inhibitor in Metastatic Urothelial Cancer
Treatment with the antibody-drug conjugate sacituzumab govitecan-hziy achieved an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer who experienced disease progression on an immune checkpoint inhibitor, according to the primary analysis of the...
THOR Trial: Erdafitinib Improves Outcomes vs Chemotherapy in FGFR-Altered Advanced Urothelial Carcinoma
Targeted treatment with the fibroblast growth factor receptor (FGFR) inhibitor erdafitinib significantly improved overall survival, progression-free survival, and objective response rates compared with investigator’s choice of chemotherapy in patients with advanced urothelial cancers and FGFR2/3...
Rucaparib vs Physician’s Choice of Single-Agent Therapy in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
As reported in The New England Journal of Medicine by Karim Fizazi, MD, PhD, of Gustave Roussy Institute, Paris-Saclay University, and colleagues, the phase III TRITON3 trial has shown significantly improved progression-free survival with rucaparib vs physician-selected single-agent therapy in the...
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The addition of the androgen receptor inhibitor darolutamide to androgen-deprivation therapy and docetaxel reduced the risk of death by 30% compared with androgen-deprivation therapy plus docetaxel in patients with metastatic hormone-sensitive prostate cancer, according to a post hoc analysis of...
PROpel Trial: Improvement in Progression-Free Survival With First-Line Olaparib Plus Abiraterone in Metastatic Prostate Cancer
The addition of the PARP (poly [ADP-ribose] polymerase) inhibitor olaparib to standard-of-care abiraterone in the first-line setting of metastatic castration-resistant prostate cancer achieved longer progression-free survival vs abiraterone alone, as demonstrated in the final results of the phase...
Three Studies From ASCO 2023 Focus on Metastatic Castration-Resistant Prostate Cancer
Presented here are summaries of three abstracts from the 2023 ASCO Annual Meeting that are pertinent for patients with metastatic castration-resistant prostate cancer. The first two focus on men with homologous recombinant repair (HRR) gene alterations, including BRCA1/2. In the first study,...
COSMIC-313: Triplet Therapy Is Active in Renal Cell Carcinoma, but Toxicities Pose a Challenge
The addition of cabozantinib to nivolumab plus ipilimumab prolonged progression-free survival in untreated intermediate-risk patients with advanced renal cell carcinoma (RCC), according to the first results of the phase III COSMIC-313 trial. These findings were presented as a Presidential Symposium ...
CLEAR Trial: Continued Survival Benefit With First-Line Lenvatinib Plus Pembrolizumab in Advanced Kidney Cancer
At extended follow-up, lenvatinib plus pembrolizumab showed sustained superiority over sunitinib for overall and progression-free survival as first-line treatment for advanced renal cell carcinoma.1 The majority of the benefit was observed in intermediate- and poor-risk subgroups, according to the...
Genitourinary Oncology 2023 Almanac
It is an exciting time in the development of new treatments for urologic cancers. There have been a number of major changes both in advanced disease and in the perioperative setting over the past year. Urothelial and Bladder Cancers In urothelial cancer, at last, we have randomized data supporting...
Recent FDA Approvals in Hematologic Oncology
Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and new indications for older therapeutic agents used in hematologic oncology. Glofitamab for DLBCL On June 15, 2023, the FDA granted accelerated approval to glofitamab-gxbm (Columvi) for...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Elranatamab Induces Responses in Many Patients With Resistant Multiple Myeloma in Phase II Trial
The promise of bispecific monoclonal antibodies in multiple myeloma continues to heighten as yet another one appears to be active. In a study reported at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition,1 almost two-thirds of patients with triple-refractory disease who...
CARTITUDE-4: Ciltacabtagene Autoleucel Beneficial in Early Myeloma Relapse
Compared with the standard of care for relapsed multiple myeloma, a single infusion of ciltacabtagene autoleucel was associated with a significant 74% reduction in the risk of disease progression in patients with lenalidomide-refractory multiple myeloma after one to three relapses, the phase III...
Ruxolitinib Demonstrates Clinical Activity in a Phase II Trial of Chronic Myelomonocytic Leukemia
In a phase II trial, treatment with the JAK2 inhibitor ruxolitinib resulted in clinical activity in two-thirds of patients with chronic myelomonocytic leukemia (CMML) with splenomegaly or an otherwise high disease symptom burden. The magnitude of symptomatic benefit was similar to that observed in...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
CAR T-Cell Therapy vs Chemoimmunotherapy in Second-Line Treatment of Resistant Large B-Cell Lymphoma
New research has confirmed the superiority of lisocabtagene maraleucel over the standard of care for the second-line treatment of primary refractory or early relapsed large B-cell lymphoma, according to data presented by lead study author Jeremy S. Abramson, MD, Associate Professor of Medicine at...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
SWOG S1826: Nivolumab Plus AVD Surpasses Standard-of-Care Combination Regimen in Patients With Advanced Hodgkin Lymphoma
The addition of nivolumab, an immune checkpoint inhibitor, to chemotherapy significantly improved progression-free survival in adults and children with advanced classical Hodgkin lymphoma with reduced toxicity compared with standard-of-care brentuximab vedotin plus chemotherapy, according to the...
ZUMA-7: Primary Overall Survival Analysis Supports Axicabtagene Ciloleucel as Second-Line Therapy in Advanced Lymphoma
In the primary overall survival analysis of ZUMA-7, second-line treatment with axicabtagene ciloleucel significantly improved overall survival compared with high-dose therapy plus autologous stem cell transplantation (auto-HCT) in patients with early relapsed or refractory large B-cell lymphoma....
Hematologic Oncology 2023 Almanac
The past several months have brought significant advances within the field of hematologic oncology. Here we will review some key updates focusing on pivotal clinical trials and new drug approvals. Advances in Lymphoma Presented at the 2023 ASCO Annual Meeting, SWOG S1826 compared nivolumab plus...
Impact of Interventions to Promote Adjuvant Endocrine Therapy Adherence Among Breast Cancer Survivors
In a systematic review and meta-analysis reported in the Journal of Clinical Oncology, Bright et al found that interventions to promote adjuvant endocrine therapy adherence in breast cancer survivors were successful overall compared with control conditions, although some interventions appeared to...
FDA Grants Accelerated Approval to Talquetamab-tgvs for Treatment of Relapsed or Refractory Multiple Myeloma
On August 9, the U.S. Food and Drug Administration (FDA) granted accelerated approval to the bispecific antibody talquetamab-tgvs (Talvey) for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, an...
Overcoming Financial Toxicity From Cancer
I knew the moment my fingers found a lump in my left breast, in 2018, that it was cancer, and I wondered if I was going to die. My maternal grandmother had been diagnosed with breast cancer when she was 39, the same age I was when I discovered the mass in my breast. She died 5 years later. Divorced ...
CAR T-Cell Therapies: Trends and Indications
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. With this installment, we launch a new series of articles on commercially available chimeric antigen receptor (CAR) T-cell therapies. Syed Ali Abutalib, MD, and Jennifer N. ...
Talazoparib With Enzalutamide in HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer
On June 20, 2023, the PARP inhibitor talazoparib was approved for use with enzalutamide in homologous recombination repair (HRR) gene–mutated metastatic castration-resistant prostate cancer.1 Supporting Efficacy Data Approval was based on findings in the multicohort, double-blind TALAPRO-2 trial...
